Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial

MONTREAL, June 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will hold a video conference call on Tuesday, June 13, 2023, to update investors and analysts on the Phase 1 trial of its lead peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), for the treatment of solid tumors.

During the call, Theratechnologies will provide insights on preliminary Phase 1 safety and efficacy data that were presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), as well as the U.S. Food and Drug Administration’s (FDA) recent agreement to the Company’s amended Phase 1 trial protocol. Both events are significant milestones in the development of sudocetaxel zendusortide, a PDC that targets the sortilin (SORT1) receptor, and a product of Theratechnologies’ SORT1+ Technology platform.

Paul Lévesque, President and Chief Executive Officer of Theratechnologies, will host the call, which will feature presentations from the Company’s Senior Vice President and Chief Medical Officer, Christian Marsolais, Ph.D., as well as from investigators from the Phase 1 trial. Presenters will be available to answer questions following prepared remarks.

Registration information:            

Title:	Oncology Investigator Call for Investors & Analysts: Phase 1 Trial Update
Date:	June 13, 2023
Time:	10:00 AM EDT
Webcast link:	https://edge.media-server.com/mmc/p/u5gusxvs
Dial in:	1-888-317-6003 (toll free) or 1-412-317-6061 (International) (Participant entry #: 2792560)

An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.

About SORT1+ Technology and Sudocetaxel Zendusortide (TH1902)
Theratechnologies has established its SORT1+ Technology platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and trafficking. Expression of SORT1 is associated with aggressive disease, poor prognosis, and decreased survival. It is estimated that SORT1 is expressed in 40% to 90% of endometrial, ovarian, colorectal, triple-negative breast (TNBC), and pancreatic cancers, making this receptor an attractive target for anticancer drug development.